BDZ,

While looking at the AHA presentation again,... I saw the low LDL numbers and they are even better than the amazing under 60 eGFR group,... with more patients in the low LDL group as well.

So with low LDL being considered a good thing,... will it be possible to actually market Apabetalone for Diabetic patients with CVD and low LDL,..?

Also will they analyse how many patients who ended up being in the low LDL group, that were also in the low eGFR group,...? So those who had low LDL and under 60 eGFR,...?

Thanks!